Suppr超能文献

全球来自旋毛虫病高危地区且将在美国开始皮质类固醇治疗的人群的治疗策略的成本效益。

Cost-effectiveness of treatment strategies for populations from strongyloidiasis high-risk areas globally who will initiate corticosteroid treatment in the USA.

机构信息

Division of Global Migration and Quarantine, U.S. Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.

Infectious Disease Section, Minneapolis Veterans Affairs Health Care System, Minneapolis, MN 55417, USA.

出版信息

J Travel Med. 2024 Aug 3;31(6). doi: 10.1093/jtm/taad054.

Abstract

BACKGROUND

The risk of developing strongyloidiasis hyperinfection syndrome appears to be elevated among individuals who initiate corticosteroid treatment. Presumptive treatment or treatment after screening for populations from Strongyloides stercoralis-endemic areas has been suggested before initiating corticosteroids. However, potential clinical and economic impacts of preventative strategies have not been evaluated.

METHODS

Using a decision tree model for a hypothetical cohort of 1000 individuals from S. stercoralis-endemic areas globally initiating corticosteroid treatment, we evaluated the clinical and economic impacts of two interventions, 'Screen and Treat' (i.e. screening and ivermectin treatment after a positive test), and 'Presumptively Treat', compared to current practice (i.e. 'No Intervention'). We evaluated the cost-effectiveness (net cost per death averted) of each strategy using broad ranges of pre-intervention prevalence and hospitalization rates for chronic strongyloidiasis patients initiating corticosteroid treatment.

RESULTS

For the baseline parameter estimates, 'Presumptively Treat' was cost-effective (i.e. clinically superior with cost per death averted less than a threshold of $10.6 million per life) compared to 'No Intervention' ($532 000 per death averted) or 'Screen and Treat' ($39 000 per death averted). The two parameters contributing the most uncertainty to the analysis were the hospitalization rate for individuals with chronic strongyloidiasis who initiate corticosteroids (baseline 0.166%) and prevalence of chronic strongyloidiasis (baseline 17.3%) according to a series of one-way sensitivity analyses. For hospitalization rates ≥0.022%, 'Presumptively Treat' would remain cost-effective. Similarly, 'Presumptively Treat' remained preferred at prevalence rates of ≥4%; 'Screen and Treat' was preferred for prevalence between 2 and 4% and 'No Intervention' was preferred for prevalence <2%.

CONCLUSIONS

The findings support decision-making for interventions for populations from S. stercoralis-endemic areas before initiating corticosteroid treatment. Although some input parameters are highly uncertain and prevalence varies across endemic countries, 'Presumptively Treat' would likely be preferred across a range for many populations, given plausible parameters.

摘要

背景

在开始皮质类固醇治疗的个体中,发展强中感染综合征的风险似乎升高。有人建议在开始皮质类固醇治疗之前,对来自 Strongyloides stercoralis 流行地区的人群进行筛查并进行治疗,或进行推定治疗。然而,预防策略的潜在临床和经济影响尚未得到评估。

方法

我们使用决策树模型,对来自全球 Strongyloides stercoralis 流行地区的 1000 名个体进行了假设队列分析,评估了两种干预措施(即筛查和阳性检测后用伊维菌素治疗)和“推定治疗”与当前实践(即“无干预”)相比的临床和经济影响。我们使用广泛的皮质类固醇治疗慢性 Strongyloides 患者住院率和治疗前流行率,评估了每种策略的成本效益(每例死亡避免的净成本)。

结果

对于基线参数估计,与“无干预”(每例死亡避免 532,000 美元)或“筛查和治疗”(每例死亡避免 39,000 美元)相比,“推定治疗”在成本效益方面具有优势(即临床效果更好,每例死亡避免的成本低于 1060 万美元的阈值)。对分析影响最大的两个参数是接受皮质类固醇治疗的慢性 Strongyloides 患者的住院率(基线为 0.166%)和慢性 Strongyloides 的流行率(基线为 17.3%)。根据一系列单因素敏感性分析,对于住院率≥0.022%,“推定治疗”仍具有成本效益。同样,在流行率≥4%的情况下,“推定治疗”仍然是首选;在流行率在 2%至 4%之间时,“筛查和治疗”是首选;而在流行率<2%时,“无干预”是首选。

结论

这些发现支持针对来自 Strongyloides stercoralis 流行地区人群的皮质类固醇治疗前干预措施的决策。尽管一些输入参数高度不确定,并且流行率在流行国家之间有所不同,但在许多人群中,根据合理的参数,“推定治疗”可能是首选。

相似文献

6
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.

本文引用的文献

4
Helminth infections in the US military: from strongyloidiasis to schistosomiasis.
J Travel Med. 2021 Aug 27;28(6). doi: 10.1093/jtm/taab004.
7
The Global Prevalence of Infection.
Pathogens. 2020 Jun 13;9(6):468. doi: 10.3390/pathogens9060468.
8
Prevalence of strongyloidiasis and schistosomiasis among migrants: a systematic review and meta-analysis.
Lancet Glob Health. 2019 Feb;7(2):e236-e248. doi: 10.1016/S2214-109X(18)30490-X.
9
Strongyloides stercoralis infection in a migrant on dialysis.
J Travel Med. 2018 Jan 1;25(1). doi: 10.1093/jtm/tay143.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验